Contraceptive Technology Update – October 1, 2011
October 1, 2011
View Archives Issues
-
HHS adds contraception coverage — What is the next step?
How many times have you prescribed oral contraceptives (OCs) for a woman at one visit, only to find that she has discontinued the method by the next exam due to financial inability to cover her insurance copay on the pill pack? -
DMPA: Time to repeal black box warning?
The Food and Drug Administration (FDA) added a "black box" warning in 2004 to the contraceptive injection depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City; Medroxyprogesterone Acetate Injectable Suspension USP, Teva Pharmaceuticals USA, North Wales, PA) advising that prolonged use might result in bone mineral density loss. -
Antiretroviral drugs protect against HIV
Results of three large studies, presented at the recent International AIDS Society (IAS) Conference on HIV Pathogenesis, indicate that pre-exposure prophylaxis of antiretrovirals can prevent HIV when used by heterosexual men and women. -
'Lab on a chip' eyed as screening tool option
Field test results of a integrated microfluidic-based diagnostic device indicate that the potential "lab-on-a-chip" might be able to perform complex laboratory assays in a simple, convenient manner. -
New guidance issued for breast screening
The American College of Obstetricians and Gynecologists (ACOG) has issued new breast cancer screening guidelines that recommend mammography screening be offered annually to women beginning at age 40. -
FDA issues warning on counterfeit EC
Alert your patients of a counterfeit form of emergency contraception (EC), labeled as Evital. The Food and Drug Administration (FDA) has issued a warning on the drug.